CN104602763B - 用于调节毛发生长的组合物和方法 - Google Patents

用于调节毛发生长的组合物和方法 Download PDF

Info

Publication number
CN104602763B
CN104602763B CN201380026128.9A CN201380026128A CN104602763B CN 104602763 B CN104602763 B CN 104602763B CN 201380026128 A CN201380026128 A CN 201380026128A CN 104602763 B CN104602763 B CN 104602763B
Authority
CN
China
Prior art keywords
hair
pgd2
activity
hair growth
ptgds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380026128.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN104602763A (zh
Inventor
G·科特萨雷利斯
G·菲茨杰拉德
L·卡萨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania
Original Assignee
University of Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania filed Critical University of Pennsylvania
Priority to CN201810834487.1A priority Critical patent/CN108938441A/zh
Publication of CN104602763A publication Critical patent/CN104602763A/zh
Application granted granted Critical
Publication of CN104602763B publication Critical patent/CN104602763B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A61K8/492—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid having condensed rings, e.g. indol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/69—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing fluorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A61Q7/02—Preparations for inhibiting or slowing hair growth
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/88—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving prostaglandins or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN201380026128.9A 2012-03-21 2013-03-15 用于调节毛发生长的组合物和方法 Active CN104602763B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810834487.1A CN108938441A (zh) 2012-03-21 2013-03-15 用于调节毛发生长的组合物和方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261613829P 2012-03-21 2012-03-21
US61/613,829 2012-03-21
PCT/US2013/031825 WO2013142295A1 (en) 2012-03-21 2013-03-15 Compositions and methods for regulating hair growth

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201810834487.1A Division CN108938441A (zh) 2012-03-21 2013-03-15 用于调节毛发生长的组合物和方法

Publications (2)

Publication Number Publication Date
CN104602763A CN104602763A (zh) 2015-05-06
CN104602763B true CN104602763B (zh) 2018-08-21

Family

ID=49223241

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380026128.9A Active CN104602763B (zh) 2012-03-21 2013-03-15 用于调节毛发生长的组合物和方法
CN201810834487.1A Pending CN108938441A (zh) 2012-03-21 2013-03-15 用于调节毛发生长的组合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201810834487.1A Pending CN108938441A (zh) 2012-03-21 2013-03-15 用于调节毛发生长的组合物和方法

Country Status (10)

Country Link
EP (1) EP2827952B1 (cg-RX-API-DMAC7.html)
JP (2) JP6193968B2 (cg-RX-API-DMAC7.html)
KR (1) KR102205774B1 (cg-RX-API-DMAC7.html)
CN (2) CN104602763B (cg-RX-API-DMAC7.html)
AU (4) AU2013235439B2 (cg-RX-API-DMAC7.html)
CA (1) CA2867901A1 (cg-RX-API-DMAC7.html)
EA (1) EA033143B1 (cg-RX-API-DMAC7.html)
ES (1) ES2895660T3 (cg-RX-API-DMAC7.html)
IL (1) IL234740A0 (cg-RX-API-DMAC7.html)
WO (1) WO2013142295A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE030850T2 (en) 2006-06-16 2017-06-28 Univ Pennsylvania Prostaglandin D2 receptor antagonists for the treatment of hair loss
JP2014500275A (ja) 2010-12-06 2014-01-09 フォリカ，インコーポレイテッド 禿頭症を治療するため、および毛髪の成長を促進するための方法
US11696883B2 (en) 2014-05-23 2023-07-11 Triple Hair Inc. Compositions for reducing hair loss and/or increasing hair regrowth
WO2015176161A1 (en) * 2014-05-23 2015-11-26 Triple Hair Inc. Compositions for reducing hair loss and/or increasing hair regrowth
KR102159427B1 (ko) * 2015-04-30 2020-09-24 알러간, 인코포레이티드 지방 감소를 위한 미용적 방법 및 치료적 용도
US10039703B2 (en) 2015-07-08 2018-08-07 Triple Hair Inc. Composition comprising resveratrol and melatonin for reducing hair loss and/or increasing hair regrowth
ES2947824T3 (es) * 2015-07-30 2023-08-21 Univ Pennsylvania Alelos polimórficos de un solo nucleótido del gen DP-2 humano para la detección de la susceptibilidad a la inhibición del crecimiento del cabello por antagonistas de PGD2
CN106214592B (zh) * 2016-09-09 2019-03-15 美萃国际贸易（上海）有限公司 毛囊营养液组合物及其制备方法
KR101857408B1 (ko) 2018-02-28 2018-05-14 경북대학교 산학협력단 탈모 예방 또는 치료용 조성물
GB202005548D0 (en) * 2020-04-16 2020-06-03 Hairclone Ltd Method of determining the androgen-sensitivity of a hair follicle
JP7895088B2 (ja) * 2022-06-17 2026-07-27 丸善製薬株式会社 線維芽細胞増殖因子－５（ｆｇｆ－５）産生促進剤、及びｆｇｆ－５の産生を抑制する素材の評価方法
CN119841890A (zh) * 2025-03-21 2025-04-18 杭州佰倍优生物科技有限公司 一种促进毛囊重建的血蛋白肽及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050112075A1 (en) * 2003-11-25 2005-05-26 Hwang Cheng S. Reduction of hair growth
US20100172865A1 (en) * 2010-03-18 2010-07-08 Shantha Totada R Methods of enhancing hair growth
US20110021599A1 (en) * 2006-06-16 2011-01-27 George Cotsarelis Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and bph
WO2012078649A1 (en) * 2010-12-06 2012-06-14 Follica, Inc. Methods for treating baldness and promoting hair growth

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6878522B2 (en) 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
SE0200356D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
SE0200411D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
WO2003097042A1 (en) 2002-05-16 2003-11-27 Shionogi & Co., Ltd. Pgd2 receptor antagonist
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
PL376156A1 (en) 2002-10-04 2005-12-27 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
AU2003269327A1 (en) 2002-10-21 2004-05-04 Warner-Lambert Company Llc Tetrahydroquinoline derivatives as crth2 antagonists
EP1435356A1 (en) 2003-01-06 2004-07-07 Warner-Lambert Company LLC Quinoline derivatives as CRTH2 antagonists
SE0301569D0 (sv) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
SE0302232D0 (sv) * 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
SA04250253B1 (ar) 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
WO2005040112A1 (en) 2003-10-14 2005-05-06 Oxagen Limited Compounds with pgd2 antagonist activity
GB2407318A (en) 2003-10-23 2005-04-27 Oxagen Ltd Substituted Indol-3-yl acetic acid derivatives
SE0303180D0 (sv) 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
JP5164567B2 (ja) * 2005-05-17 2013-03-21 大鵬薬品工業株式会社 慢性副鼻腔炎の重症度および再発性の検査方法
ES2391671T3 (es) * 2006-07-22 2012-11-28 Oxagen Limited Compuestos con actividad antagonista de CRTH2
EP2442802A1 (en) * 2009-06-17 2012-04-25 Aderans Research Institute, Inc. Methods and compositions for increasing trichogenic potency of dermal cells
JP2013500979A (ja) * 2009-07-31 2013-01-10 パンミラ ファーマシューティカルズ，エルエルシー． Ｄｐ２受容体アンタゴニストの皮膚用製剤
MX2012007927A (es) * 2010-01-06 2012-08-15 Panmira Pharmaceuticals Llc Antagonistas de dp2 y usos del mismo.
KR101953742B1 (ko) * 2010-02-24 2019-03-04 어드밴젠 인터내셔널 피티와이 리미티드 모발 손상 치료 또는 예방 방법 또는 모발 성장 촉진용 방법

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050112075A1 (en) * 2003-11-25 2005-05-26 Hwang Cheng S. Reduction of hair growth
US20110021599A1 (en) * 2006-06-16 2011-01-27 George Cotsarelis Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and bph
US20100172865A1 (en) * 2010-03-18 2010-07-08 Shantha Totada R Methods of enhancing hair growth
WO2012078649A1 (en) * 2010-12-06 2012-06-14 Follica, Inc. Methods for treating baldness and promoting hair growth

Also Published As

Publication number Publication date
CN104602763A (zh) 2015-05-06
JP2017197585A (ja) 2017-11-02
WO2013142295A1 (en) 2013-09-26
ES2895660T3 (es) 2022-02-22
AU2021203172A1 (en) 2021-06-10
AU2013235439B2 (en) 2017-11-23
KR20140146133A (ko) 2014-12-24
IL234740A0 (en) 2014-11-30
JP2015512393A (ja) 2015-04-27
AU2013235439A1 (en) 2014-10-30
EP2827952B1 (en) 2021-07-07
AU2019204620A1 (en) 2019-07-18
EA201491737A1 (ru) 2015-07-30
CA2867901A1 (en) 2013-09-26
EP2827952A4 (en) 2016-03-30
EA033143B1 (ru) 2019-09-30
CN108938441A (zh) 2018-12-07
EP2827952A1 (en) 2015-01-28
AU2018201331A1 (en) 2018-03-15
JP6193968B2 (ja) 2017-09-06
KR102205774B1 (ko) 2021-01-20

Similar Documents

Publication Publication Date Title
CN104602763A (zh) 用于调节毛发生长的组合物和方法
Kobayashi et al. A role of melatonin in neuroectodermal‐mesodermal interactions: the hair follicle synthesizes melatonin and expresses functional melatonin receptors
Alessandrini et al. Common causes of hair loss–clinical manifestations, trichoscopy and therapy
Telek et al. Inhibition of human hair follicle growth by endo‐and exocannabinoids
JP6923927B2 (ja) 脱毛および白毛化を抑制もしくは改善するための組成物ならびにその使用
JP7046086B2 (ja) Ｍｐｃ阻害剤を使用する育毛を促進するための組成物及び方法
JP2019519502A (ja) ヒトにおける毛髪成長を促進し、かつ／または脱毛を阻害もしくは遅延させる化合物、ならびにかかる使用のための組成物
US20150072963A1 (en) Compositions and methods for regulating hair growth
US20220249426A1 (en) Inhibitors of the sting pathway for the treatment of hidradenitis suppurativa
Mahdi et al. Amlodipine topical cream: an effective hair growth promoter for an alopecia mouse model via VEGF-mediated angiogenesis and vasodilation
WO2021147740A1 (zh) Mapk/erk通路抑制剂在拮抗皮肤老化与辐射性皮肤早衰中的应用
CN108472510A (zh) 用于检测pgd2对毛发生长抑制的易感性的人dp-2基因的单核苷酸多态性等位基因
Tabri et al. The efectiveness of 0.03% bimatoprost solution vs minoxidil 5% in androgenic alopecia
WO2019094798A1 (en) Methods and compositions for promoting or inducing hair growth
Alessandrini et al. Summary of hair diseases: cicatricial and non-cicatricial
US20230035479A1 (en) Methods and compositions for reducing hair greying
WO2023056029A1 (en) Beta3-adrenergic agonists for treatment of disorders of hair growth
KR20240039351A (ko) RhoA 활성화 인자를 유효성분으로 포함하는 피부 보습 및 피부 장벽 강화용 조성물
CN119654131A (zh) 用于促进毛发生长和改善美观方面的嗅觉受体2a4/7激动剂
Khidhir Human scalp hair follicles express prostaglandin E2 lipid mediator and receptors for Pge2
Blume-Peytavi et al. P-01: A pilot study-24 weeks topical treatment by latanoprost 0.1% increases hair growth in androgenetic alopecia
WO2017053939A1 (en) Method and composition for treatment of hair loss

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant